Nazca Capital acquired a 85% stake of Diater Laboratorio de Diagnóstico y Aplicaciones Terapéuticas

Windcorp Translink, member of Translink Corporate Finance is pleased to announce that they have served as exclusive M&A advisor to Nazca Capital S.G.E.I.C., S.A. in the acquisition of a 85% stake of Diater Laboratorio de Diagnóstico y Aplicaciones Terapeuticas, S.A. The transaction is valued at EUR 45m, representing nine times the EBITDA of about EUR 5m that Diater posted in 2018.

Diater, founded in 1999 and based in Madrid, is a biopharmaceutical company specialized in allergic diseases and focused on developing, manufacturing and marketing allergen extracts for the diagnosis and treatment of allergic diseases, an area in which it has an extensive catalog and has become a market reference. Diater reached a sales volume of EUR 17m and an EBITDA of EUR 5m at the close of 2018 and expects to reach EUR 20m sales in 2019.

Nazca is a Spanish Private Equity management company which invests in non-quoted Spanish medium sized companies (sales between €30 and €200 million), through acquisition of shares and capital increases. Since 2001, Nazca has closed more than 55 transactions, invested EUR 480m of commitments. Currently, Nazca is investing their fourth fund, Nazca IV, with EUR 275 million of commitments from high quality international institutional investors from Europe.

With the incorporation of Nazca in the shareholding, it seeks to boost the company’s growth, supporting Diater in the development of new products, R&D and in the expansion into new markets worldwide.